Summary & Overview
HCPCS Q4162: Woundex Flow (Bioskin Flow), 0.5 cc
HCPCS Level II code Q4162 denotes a 0.5 cc unit of Woundex flow (bioskin flow), a topical biologic product used in wound management. Nationally, such HCPCS Level II supply codes are important for standardizing billing and reimbursement for advanced wound-care products and for tracking utilization of biologic topical agents across outpatient settings.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical context and typical sites of service, plus a description of what to expect in payer coverage reviews. The publication outlines the types of benchmarks and policy items that frequently accompany HCPCS Level II supply codes, including coverage criteria, billing practices, and unit-based reimbursement considerations.
This piece is intended to orient clinicians, billing staff, and policy analysts to the code’s purpose and operational context. It summarizes the clinical application of the product, highlights the payers commonly involved in coverage decisions, and identifies the categories of information typically examined in payer policies and benchmarking reports. Data not available in the input indicates that specifics such as payer policy details, rates, and associated taxonomies are not included here.
Billing Code Overview
HCPCS Level II code Q4162 describes Woundex flow, bioskin flow, 0.5 cc, a biologic topical/dermal product intended for use in wound care. The service type is topical biologic wound therapy. The typical site of service for this product is outpatient wound care settings, including wound clinics, ambulatory surgical centers, and physician offices where topical biologic agents are applied to chronic or complex wounds.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic or non-healing cutaneous wound (for example, a diabetic foot ulcer, venous stasis ulcer, or pressure injury) presenting to a wound care clinic or outpatient surgical center for advanced topical therapy. The clinician prepares the wound by cleansing and debridement as indicated, assesses wound dimensions and surrounding skin, and determines that application of a biosynthetic flowable wound matrix such as Q4162 (Woundex flow, bioskin flow, 0.5 cc) is appropriate to fill and cover irregular wound beds and promote granulation. The product is supplied in a 0.5 cc unit; the clinician documents units used, lot numbers, and method of application. Typical workflow steps include patient assessment, wound bed preparation (sharp or mechanical debridement if indicated), hemostasis, application of the flowable matrix into the wound cavity, placement of secondary dressing, and patient instructions for dressing changes and follow-up wound assessments. The procedure commonly occurs in an outpatient wound care clinic, ambulatory surgical center, or hospital outpatient department. Documentation includes indication, wound measurements, number of Q4162 units used, provider performing the procedure, and any local anesthesia or sedation when applicable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier |